Associated Papers
Association of SLCO1B3 and SLCO1B1 Polymorphisms with Methotrexate Efficacy and Toxicity in Saudi Rheumatoid Arthritis Patients.
Magadmi R et al.
Pharmaceuticals (basel, Switzerland), 2025
When the same treatment has different response: The role of pharmacogenomics in statin therapy.
Zheng E et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2024
Genetic Diversity in Drug Transporters: Impact in African Populations.
Rajman I et al.
Clinical and Translational Science, 2020
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition.
Zhou F et al.
Advanced Drug Delivery Reviews, 2017
Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Chen S et al.
Drug Metabolism Reviews, 2016
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.
Emami Riedmaier A et al.
Journal of Clinical Pharmacology, 2016
Heritability of metoprolol and torsemide pharmacokinetics.
Matthaei J et al.
Clinical Pharmacology and Therapeutics, 2015
Pharmacogenetics of membrane transporters: a review of current approaches.
Sissung TM et al.
Methods in Molecular Biology (clifton, N.j.), 2014
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1.
Nies AT et al.
Genome Medicine, 2013
OATP1B1 polymorphism as a determinant of erythromycin disposition.
Lancaster CS et al.
Clinical Pharmacology and Therapeutics, 2012
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.
de Graan AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
UGT1A1, SLCO1B1, and SLCO1B3 polymorphisms vs. neonatal hyperbilirubinemia: is there an association?
Alencastro de Azevedo L et al.
Pediatric Research, 2012
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C et al.
Drug Metabolism Reviews, 2010
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Romaine SP et al.
The Pharmacogenomics Journal, 2010
Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.
Han JY et al.
Lung Cancer (amsterdam, Netherlands), 2008
The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members.
Seithel A et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy.
Ieiri I et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
Pharmacogenomics of human OATP transporters.
König J et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2006
Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.
Tirona RG et al.
The Journal of Biological Chemistry, 2001
The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature.
Anabtawi N et al.
Expert Opinion on Drug Metabolism & Toxicology, 0